Want to see FR:ALVAL full AI Analyst Report?
Top Page
Valbiotis SA
(ALVAL)
Select Model
Select Model
Rating:41Neutral
Price Target:
€0.68
▼(-16.30% Downside)
Action:Reiterated
Date:09/30/26
The score is held down primarily by weak financial performance—persistent losses, negative margins, and ongoing cash burn that implies continued external funding needs. Technicals also remain bearish with the price below all major moving averages and negative MACD, while valuation is constrained by a negative P/E and no dividend yield support.
Positive Factors
Recent Revenue Rebound
The reported 417.1% revenue-growth figure indicates a substantial recent expansion in sales activity. If the rebound can be sustained, it would improve operating leverage and support commercialization investment, although historical volatility means durability still depends on execution.
Negative Factors
Persistent Cash Burn
Sustained negative operating and free cash flow shows that the business is not currently self-funding. Continued cash burn can require repeated external capital, potentially limiting strategic flexibility and increasing the risk that future financing becomes a recurring feature of the operating model.
Read all positive and negative factors
Positive Factors
Negative Factors
Recent Revenue Rebound
The reported 417.1% revenue-growth figure indicates a substantial recent expansion in sales activity. If the rebound can be sustained, it would improve operating leverage and support commercialization investment, although historical volatility means durability still depends on execution.
Read all positive factors
Valbiotis SA (ALVAL) vs. iShares MSCI France ETF (EWQ)
Market Cap
€22.84M
Dividend YieldN/A
Average Volume (3M)68.33K
Price to Earnings (P/E)―
Beta (1Y)-0.13
Revenue Growth417.14%
EPS Growth22.08%
CountryFR
Employees50
SectorConsumer Defensive
Sector Strength42
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.49
Shares Outstanding35,538,235
10 Day Avg. Volume101,843
30 Day Avg. Volume68,325
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.36
Price to Sales (P/S)18.17
P/FCF Ratio-2.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.24
Revenue Forecast (FY)€3.05M
Valbiotis SA Business Overview & Revenue Model
Company Description
Valbiotis SA is a French company, established in 2014 and headquartered in Périgny, that specializes in the research and development of nutritional health products. Its primary focus is on preventing and managing metabolic and cardiovascular disea...
How the Company Makes Money
Valbiotis makes money primarily by commercializing its nutrition-health products and/or the underlying ingredients/formulations it develops, generating revenue from product sales (direct-to-consumer and/or through distribution channels such as pha...
Valbiotis SA Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
42
Neutral
Cash Flow
21
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 905.00K | 175.00K | 4.73M | 785.00K | 298.00K |
| Gross Profit | -1.17M | -2.44M | 2.69M | 767.00K | 282.00K |
| EBITDA | -9.28M | -9.17M | -6.41M | -11.13M | -9.14M |
| Net Income | -9.42M | -10.03M | -7.37M | -12.31M | -8.68M |
Balance Sheet | |||||
| Total Assets | 14.39M | 19.61M | 33.31M | 27.17M | 28.48M |
| Cash, Cash Equivalents and Short-Term Investments | 8.68M | 11.58M | 25.02M | 20.83M | 21.82M |
| Total Debt | 5.09M | 5.72M | 6.88M | 7.18M | 7.59M |
| Total Liabilities | 7.43M | 9.24M | 13.71M | 13.86M | 14.25M |
| Stockholders Equity | 6.96M | 10.37M | 19.60M | 13.31M | 14.23M |
Cash Flow | |||||
| Free Cash Flow | -8.19M | -11.80M | -8.30M | -9.48M | -7.58M |
| Operating Cash Flow | -8.04M | -11.54M | -8.06M | -9.19M | -7.16M |
| Investing Cash Flow | -77.00K | -61.00K | -250.00K | -197.00K | -7.00K |
| Financing Cash Flow | 5.21M | -1.84M | 12.49M | 8.40M | 14.40M |
Valbiotis SA Technical Analysis
Negative
0.81
Price Trends
0.78
Negative
0.83
Negative
0.89
Negative
Market Momentum
-0.04
Positive
28.71
Positive
6.62
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALVAL, the sentiment is Negative. The current price of 0.81 is above the 20-day moving average (MA) of 0.73, above the 50-day MA of 0.78, and below the 200-day MA of 0.89, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 28.71 is Positive, neither overbought nor oversold. The STOCH value of 6.62 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALVAL.
Valbiotis SA Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
60 Neutral | €4.83M | 8.24 | ― | ― | -40.95% | -39.70% | |
47 Neutral | €716.20M | -5.59 | -1625.48% | ― | -99.64% | 68.67% | |
46 Neutral | €7.38M | -0.35 | 33.88% | ― | ― | ― | |
44 Neutral | €55.96M | -5.03 | -33.99% | ― | 16.41% | 44.74% | |
42 Neutral | €460.56M | -4.56 | 279.22% | ― | 27.70% | -162.89% | |
41 Neutral | €22.84M | -1.30 | -100.77% | ― | 417.14% | 22.08% |
* Consumer Defensive Sector Average
FR:ALVAL
Valbiotis SA
0.64
-0.14
-18.02%
FR:GNFT
Genfit
9.30
5.87
171.45%
FR:IVA
Inventiva
2.97
-1.79
-37.64%
FR:POXEL
Poxel SA
0.13
-0.28
-67.32%
FR:ALGAE
Fermentalg SA
0.44
-0.05
-11.02%
FR:ALPAT
Plant Advanced Technologies SA
4.20
-4.66
-52.60%
Valbiotis SA Corporate Events
Valbiotis Study Clears Path for Launch of Liver Health Product
Sep 22, 2026
Valbiotis reported positive results from its randomized, placebo-controlled Cardio-Liver study in 71 overweight or obese volunteers with hepatic steatosis, showing Steadrive reduces liver fat and improves several metabolic parameters. These findin...
Valbiotis updates share capital and voting rights, reinforces governance transparency
Sep 7, 2026
Valbiotis SA has published its monthly regulatory update on the composition of its share capital and voting rights as of August 31, 2026, in line with Article 223-16 of the AMF’s General Regulation. The company reports 35,538,234 shares outs...
Valbiotis Reports July 2026 Share Capital and Voting Rights
Aug 17, 2026
Valbiotis SA has reported its monthly share capital and voting rights position as of July 31, 2026, in line with French market regulation. The company’s share capital stands at 35,538,234 shares, corresponding to 36,250,779 theoretical votin...
Valbiotis Backs France’s Cardiovascular Prevention Push
Jul 27, 2026
Valbiotis is positioning itself as a specialist in preventive cardiometabolic solutions, offering clinically tested ranges like ValbiotisPRO and ValbiotisPLUS that address cholesterol, metabolic health, cardio-circulation and related symptoms. The...
Valbiotis’ Totum•63 wins major scientific validation with Nature Communications publication
Jul 22, 2026
Valbiotis has secured major international scientific recognition for its plant-based ingredient Totum•63, with results from the REVERSE-IT clinical trial published in the peer-reviewed journal Nature Communications. The study, conducted over...
Valbiotis Reports Active Use of Liquidity Contract in First Half of 2026
Jul 22, 2026
Valbiotis has released its half-year report on the liquidity contract managed by Portzamparc – Groupe BNP Paribas, detailing the cash and share position held to support trading in its stock. As of June 30, 2026, the liquidity account held 45...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.